Insmed to Present Three Late-Breaking TPIP Abstracts at CHEST 2026
Image
Bridgewater, N.J. – – October 14, 2026 -- Insmed (Nasdaq: INSM) will present four abstracts on its investigational inhaled therapy treprostinil palmitil inhalation powder (TPIP) at CHEST 2026 in Phoenix, three of them late-breaking, and two ARIKAYCE abstracts at IDWeek 2026 in Washington, D.C. CHEST runs Oct. 18–21 and IDWeek runs Oct. 21–24.
Chief Medical Officer Martina Flammer said the presentations span the company's respiratory portfolio of BRINSUPRI, TPIP and ARIKAYCE.